...manufacturing. Gharib was CFO of Stemedica Cell Technologies Inc.; Reddy was head of CMC at Landos Biopharma Inc....

...this week, but it has already invested in two therapeutics companies: Quellis Biosciences Inc. and Landos Biopharma Inc....
...Quellis; Garabedian and PXV Partner Fred Callori hold board seats. PXV contributed $11.6 million to Landos’...
...first-in-class oral small molecule targets lanC like 2 (LANCL2) (see “$60M B Round to Propel Landos...

...Exchange. The firm has invested in Beta Bionics Inc., Frequency Therapeutics Inc. (NASDAQ:FREQ), Immunocore Ltd., Landos Biopharma Inc....

...BT-11. Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he expects the funding to last Landos Biopharma Inc....
...investor Perceptive Advisors, via the Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund, co-led Landos'...
...is chairman and CEO of the accelerator and a Landos board member (see "Clear for Landos"...

...inhibition can lead to significant side effects including infection and cancer, said CEO Josep Bassaganya-Riera. Landos...
...to exert a broader effect because it activates multiple pathways that lead to decreased inflammation. Landos...
...According to BCIQ, there are no NLRX1 agonists in the clinic for IBD. Bassaganya-Riera said Landos...

...On Sept. 21, Landos Biopharma Inc. (Blacksburg, Va.) spun out of life sciences accelerator Xontogeny LLC (Boston, Mass...
...enable Landos to complete Phase I testing of BT-11 for Crohn's disease by early 2019. Landos...
...the number of companies in the accelerator. Garabedian joined Landos’ board. Landos Biopharma Inc. , Blacksburg, Va. Alicia Parker BT-11 Landos Biopharma Inc. Xontogeny...

...enable Landos to complete Phase I testing of BT-11 for Crohn's disease by early 2019. Landos...
...the number of companies in the accelerator. Garabedian joined Landos’ board. Virginia Li Xontogeny LLC LanC like 2 (LANCL2) BT-11 Landos Biopharma Inc....